我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
247
19 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1817
进行中（未招募）
7
2.8%
已完成
123
49.8%
Enrolling By Invitation
3
1.2%
尚未招募
9
3.6%
招募中
40
16.2%
暂停
2
0.8%
终止
5
2.0%
Unknown
52
21.1%
撤回
6
2.4%
暂无批准数据
- Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences. - The platform discovered that 37% of identified tumor antigens were Cryptigens, which are immunogenic, shared among tumor samples, and could contribute to immune checkpoint blockade responses. - This research challenges the conventional focus on mutated tumor antigens and validates unmutated sequences as actionable targets for cancer immunotherapy. - The findings distinguish Epitopea's approach from other immunotherapy companies and support the development of accessible off-the-shelf RNA-based immunotherapies.
